These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 24815944)
1. Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation. Wang D; Zhao J; Liu X; Sun F; Zhou Y; Teng L; Li Y Eur J Pharm Sci; 2014 Aug; 60():40-8. PubMed ID: 24815944 [TBL] [Abstract][Full Text] [Related]
2. Self-assembled drug delivery system based on low-molecular-weight bis-amide organogelator: synthesis, properties and in vivo evaluation. Li Z; Cao J; Li H; Liu H; Han F; Liu Z; Tong C; Li S Drug Deliv; 2016 Oct; 23(8):3168-3178. PubMed ID: 26912188 [TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of 12-HSA-based organogels as injectable implants for the controlled delivery of hydrophilic and lipophilic therapeutic agents. Esposito CL; Tardif V; Sarrazin M; Kirilov P; Roullin VG Mater Sci Eng C Mater Biol Appl; 2020 Sep; 114():110999. PubMed ID: 32993979 [TBL] [Abstract][Full Text] [Related]
4. Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants. Motulsky A; Lafleur M; Couffin-Hoarau AC; Hoarau D; Boury F; Benoit JP; Leroux JC Biomaterials; 2005 Nov; 26(31):6242-53. PubMed ID: 15916802 [TBL] [Abstract][Full Text] [Related]
5. Characterization of organogel as a novel oral controlled release formulation for lipophilic compounds. Iwanaga K; Sumizawa T; Miyazaki M; Kakemi M Int J Pharm; 2010 Mar; 388(1-2):123-8. PubMed ID: 20045041 [TBL] [Abstract][Full Text] [Related]
6. Microsphere delivery of Risperidone as an alternative to combination therapy. D'Souza S; Faraj J; DeLuca P Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159 [TBL] [Abstract][Full Text] [Related]
7. Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery. Boddu SH; Bonam SP; Wei Y; Alexander K Int J Pharm Compd; 2014; 18(3):256-61. PubMed ID: 25306775 [TBL] [Abstract][Full Text] [Related]
8. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Wang L; Wang A; Zhao X; Liu X; Wang D; Sun F; Li Y Int J Pharm; 2012 May; 427(2):284-92. PubMed ID: 22387369 [TBL] [Abstract][Full Text] [Related]
9. Self-assembled L-alanine derivative organogel as in situ drug delivery implant: characterization, biodegradability, and biocompatibility. Wang K; Jia Q; Han F; Liu H; Li S Drug Dev Ind Pharm; 2010 Dec; 36(12):1511-21. PubMed ID: 21050137 [TBL] [Abstract][Full Text] [Related]
10. A novel flunarizine hydrochloride-loaded organogel for intraocular drug delivery in situ: Design, physicochemical characteristics and inspection. Dai M; Bai L; Zhang H; Ma Q; Luo R; Lei F; Fei Q; He N Int J Pharm; 2020 Feb; 576():119027. PubMed ID: 31953090 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier. Hyun H; Kim YH; Song IB; Lee JW; Kim MS; Khang G; Park K; Lee HB Biomacromolecules; 2007 Apr; 8(4):1093-100. PubMed ID: 17326678 [TBL] [Abstract][Full Text] [Related]
12. Propolis organogel as a novel topical delivery system for treating wounds. Balata G; El Nahas HM; Radwan S Drug Deliv; 2014 Feb; 21(1):55-61. PubMed ID: 24295500 [TBL] [Abstract][Full Text] [Related]
13. DEVELOPMENT OF OLANZAPINE LOADED PNA MICROGELS FOR DEPOT DRUG DELIVERY IN TREATMENT OF SCHIZOPHRENIA: IN VITRO AN IN VIVO RELEASE PROFILE. Pervaiz F; Ahmad M; Hussain T; Idrees A; Yaqoob A; Abbas K Acta Pol Pharm; 2016; 73(1):175-81. PubMed ID: 27008812 [TBL] [Abstract][Full Text] [Related]
14. Application of organogels as oral controlled release formulations of hydrophilic drugs. Iwanaga K; Kawai M; Miyazaki M; Kakemi M Int J Pharm; 2012 Oct; 436(1-2):869-72. PubMed ID: 22766444 [TBL] [Abstract][Full Text] [Related]
15. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Citrome L Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481 [TBL] [Abstract][Full Text] [Related]
16. Topical delivery of aceclofenac from lecithin organogels: preformulation study. Shaikh IM; Jadhav KR; Gide PS; Kadam VJ; Pisal SS Curr Drug Deliv; 2006 Oct; 3(4):417-27. PubMed ID: 17076644 [TBL] [Abstract][Full Text] [Related]
17. Pluronic lecithin organogel as a topical drug delivery system. Pandey M; Belgamwar V; Gattani S; Surana S; Tekade A Drug Deliv; 2010 Jan; 17(1):38-47. PubMed ID: 22747074 [TBL] [Abstract][Full Text] [Related]
18. Organogels based on amino acid derivatives and their optimization for drug release using response surface methodology. Hu B; Yan H; Sun Y; Chen X; Sun Y; Li S; Jing Y; Li H Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):266-275. PubMed ID: 31851842 [TBL] [Abstract][Full Text] [Related]
19. In situ-forming pharmaceutical organogels based on the self-assembly of L-alanine derivatives. Couffin-Hoarau AC; Motulsky A; Delmas P; Leroux JC Pharm Res; 2004 Mar; 21(3):454-7. PubMed ID: 15070096 [TBL] [Abstract][Full Text] [Related]
20. Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride. Pisal S; Shelke V; Mahadik K; Kadam S AAPS PharmSciTech; 2004 Sep; 5(4):e63. PubMed ID: 15760060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]